117
Views
1
CrossRef citations to date
0
Altmetric
Review

Managing complications following lung transplantation

, , , &
Pages 403-423 | Published online: 09 Jan 2014

References

  • Christie JD, Edwards LB, Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report – 2008. J. Heart Lung Transplant.27, 957–969 (2008).
  • de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia–reperfusion-induced lung injury. Am. J. Respir. Crit. Care Med.167, 490–511 (2003).
  • Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT working group on primary lung graft dysfunction: part II. Definition. J. Heart Lung Transplant.24, 1454–1459 (2005).
  • Christie JD, Kotloff RM, Ahya VN et al. The effect of primary graft dysfunction on survival after lung transplantation. Am. J. Respir. Crit. Care Med.171, 1312–1316 (2005).
  • Daud SA, Yusen RD, Meyers BF et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med.175, 507–513 (2007).
  • Kermeen FD, McNeil KD, Fraser JF et al. Resolution of severe ischemia–reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J. Heart Lung Transplant.26, 850–856 (2007).
  • Zamora MR, Davis RD, Keshavjee SH et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest116, 46S (1999).
  • Wittwer T, Grote M, Oppelt P, Franke U, Schaefers HJ, Wahlers T. Impact of PAF antagonist BN 52021 (ginkolide β) on post-ischemic graft function in clinical lung transplantation. J. Heart Lung Transplant.20, 358–363 (2001).
  • Shargall Y, Guenther G, Ahya VN, Ardehali A, Singhal A, Keshavjee S. Report of the ISHLT Working Group on primary lung graft dysfunction: part VI. Treatment. J. Heart Lung Transplant.24, 1489–1500 (2005).
  • Schmid RA, Boehler A, Speich R, Frey HR, Russi EW, Weder W. Bronchial anastomotic complications following lung transplantation: still a major cause of morbidity? Eur. Respir. J.10, 2872–2875 (1997).
  • Murthy SC, Blackstone EH, Gildea TR et al.; Members of Cleveland clinic’s pulmonary transplant team. Impact of anastomotic airway complications after lung transplantation. Ann. Thorac. Surg.84, 401–409 (2007).
  • McAnally KJ, Valentine VG, LaPlace SG, McFadden PM, Seoane L, Taylor DE. Effect of pre-transplantation prednisone on survival after lung transplantation. J. Heart Lung Transplant.25, 67–74 (2006).
  • Groetzner J, Kur F, Spelsberg F et al.; Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J. Heart Lung Transplant.23, 632–638 (2004).
  • Thistlewaite PA, Yung G, Kemp A et al. Airway stenoses after lung transplantation: incidence, management, and outcome. J. Thorac. Cardiovasc. Surg.136, 1569–1575 (2008).
  • Mughal MM, Gildea TR, Murthy S, Pettersson G, DeCamp M, Mehta AC. Short-term deployment of self-expanding metallic stents facilitates healing of bronchial dehiscence. Am. J. Respir. Crit. Care Med.172, 768–771 (2005).
  • Madden BP, Loke TK, Sheth AC. Do expandable metallic airway stents have a role in the management of patients with benign tracheobronchial disease? Ann. Thorac. Surg.82, 274–278 (2006).
  • Ferrer J, Roldan J, Roman A et al. Acute and chronic pleural complications in lung transplantation. J. Heart Lung Transplant.22, 1217–1225 (2003).
  • Wahidi MM, Willner DA, Snyder LD, Hardison JL, Chia JY, Palmer SM. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest135, 484–491 (2009).
  • Shitrit D, Izbicki G, Fink G et al. Late postoperative pleural effusion following lung transplantation: characteristics and clinical implications. Eur. J. Cardiovasc. Surg.23, 494–496 (2003).
  • Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J. Heart Lung Transplant.21, 271–281 (2002).
  • Cooper JD, Billingham M, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J. Heart Lung Transplant.12, 713–716 (1993).
  • Hopkins PM, McNeil K. Evidence for immunosuppression in lung transplantation. Curr. Opin. Organ Transplant.13, 477–483 (2008).
  • Hachem J, Yusen RD, Chakinala MM et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J. Heart Lung Transplant.26, 1012–1018 (2007).
  • Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am. J. Respir. Crit. Care Med.166, 440–444 (2002).
  • Stewart S, Fishbein MC, Snell GI et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J. Heart Lung Transplant.26, 1229–1242 (2007).
  • Reams BD, Musselwhite LW, Zaas DW et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am. J. Transplant.7, 2802–2808 (2007).
  • Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (campath 1H) for immunosuppressive therapy in organ transplantation. Transpl. Int.19(9), 705–714 (2006).
  • Lama VN, Murray S, Mumford JA et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single lung transplant recipients. Am. J. Respir. Crit. Care Med.172(3), 379–383 (2005).
  • Hachem RR, Chakinala MM, Yusen RD et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am. J. Respir. Crit. Care Med.169, 468–472 (2004).
  • Hachem RR, Khalifah AP, Chakinala MM et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation80, 1406–1413 (2005).
  • Bowdish ME, Arcasoy SM, Wilt JS et al. Surrogate markers and risk factors for chronic lung allograft dysfunction. Am. J. Transplant.4, 1171–1178 (2004).
  • Chalermskulrat W, Neuringer IP, Schmitz JL et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest123, 1825–1831 (2003).
  • Snell GI, Valentine VG, Vitulo P et al.; RAD B159 Study Group. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am. J. Transplant.6, 169–177 (2006).
  • Iacono AT, Johnson BA, Grgurich WF et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N. Engl. J. Med.354, 141–150 (2006).
  • Behr J, Zimmermann G, Baumgartner R et al.; The Munich Lung Transplant Group. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. Curr. Opin. Organ Transplant.13, 477–483 (2008).
  • Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr. Opin. Pharmacol.8, 286–291 (2008).
  • Crowley S, Egan JJ. Macrolide antibiotics and bronchiolitis obliterans following lung transplantation. Expert Rev. Anti Infect. Ther.3(6), 923–930 (2005).
  • Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for brocnhiolitis obliterans: results of a pilot study. Am. J. Respir. Crit. Care Med.168, 121–125 (2003).
  • Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation77, 1465–1467 (2004).
  • Yates B, Murphy DM, Forrest IA et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med.172, 772–775 (2005).
  • Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J. Heart Lung Transplant.24, 1440–1443 (2005).
  • Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med.174, 566–570 (2006).
  • Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation85, 36–41 (2008).
  • Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am. J. Transplant.5, 537–543 (2005).
  • Benden C, Speich R, Hofbauer GF et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation86, 1625–1627 (2008).
  • Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J. Transplant.4, 1033–1041 (2004).
  • Astor TL, Weill D, Cool C, Teitelbaum I, Schwarz MI, Zamora MR. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J. Heart Lung Transplant.24, 2091–2097 (2005).
  • Magro CM, Deng A, Pope-Harman A et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation74, 1273–1280 (2002).
  • Ionescu DN, Girnita AL, Zeevi A et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl. Immunol.15, 63–68 (2005).
  • Magro CM, Klinger DM, Adams PW et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am. J. Transplant.3, 1264–1272 (2003).
  • Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-α1 tubulin-specific antibodies: role in chronic lung allograft rejection. J. Immunol.180, 4487–4494 (2008).
  • Girnita AL, McCurry KR, Iacono AT et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J. Heart Lung Transplant.23, 1135–1141 (2004).
  • Palmer SM, Davis RD, Hadjiliadis D et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation74, 799–804 (2002).
  • Hadjiliadis D, Chaparro C, Reinsmoen NL et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J. Heart Lung Transplant.24, S249–S254 (2005).
  • Appel JZ 3rd, Hartwig MG, Davis RD, Reinsmoen NL. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to hla antigens. Hum. Immunol.66, 378–386 (2005).
  • Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans. Am. Clin. Climatol. Assoc.117, 199–211 (2006).
  • Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant.6, 346–351 (2006).
  • Glotz D, Antoine C, Julia P et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl. Int.17, 1–8 (2005).
  • Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med.359, 242–251 (2008).
  • Mulley W, Hudson F, Tait B et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation87, 286–289 (2009).
  • Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant.9, 201–209 (2009).
  • Vincenti F, Kirk AD. What’s next in the pipeline. Am. J. Transplant.8, 1972–1981 (2008).
  • Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am. J. Respir. Crit. Care Med.170, 22–48 (2004).
  • Mattner F, Fischer S, Weissbrodt H et al. Post-operative nosocomial infections after lung and heart transplantation. J. Heart Lung Transplant.26, 241–249 (2007).
  • Aguilar-Guisado M, Givaldá J, Ussetti P et al.; RESITRA cohort. Pneumonia after lung transplantation in the RESITRA cohort: a multicenter prospective study. Am. J. Transplant.7, 1989–1996 (2007).
  • Valentine VG, Gupta MR, Walker JE Jr et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J. Heart Lung Transplant.28, 163–169 (2009).
  • Botha P, Archer L, Anderson RL et al.Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation85, 771–774 (2008).
  • Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas Jr. Infectious complications of lung transplantation: impact of cystic fibrosis. Am. J. Respir. Crit. Care Med.149, 1601–1607 (1994).
  • Bonnvillain RW, Valentine VG, Lombard GA, La Place SG, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non cystic fibrosis patients after lung transplantation. J. Heart Lung Transplant.26, 890–897 (2007).
  • Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am. J. Respir. Crit. Care Med.164, 2102–2106 (2001).
  • Boussaud V, Guillemain R, Grenet D et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax63, 732–737 (2008).
  • Alexander BD, Petzold EW, Reller LB et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am. J. Transplant.8, 1025–1030 (2008).
  • Glanville AR, Gencay M, Tamm M et al.Chlamydia pneumoniae infection after lung transplantation. J. Heart Lung Transplant.24, 131–136 (2005).
  • Kotsimbos TC, Snell GI, Levvey B et al.Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation79, 269–275 (2005).
  • Duncan SR, Paradis IL, Yousem SA et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am. Rev. Respir. Dis.146, 1419–1425 (1992).
  • Ettinger NA, Bailey TC, Trulock EP et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am. Rev. Respir. Dis.147, 1017–1023 (1993).
  • Fishman JA, Rubin RH. Infection in organ-transplant recipients. N. Engl. J. Med.338, 1741–1751 (1998).
  • Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature331, 269–272 (1988).
  • Burns LJ, Pooley JC, Walsh DJ, Vercellotti GM, Weber ML, Kovacs A. Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins. Transplantation67, 137–144 (1999).
  • Craigen JL, Grundy JE. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation62, 1102–1111 (1996).
  • Westall G, Kotsimbos T, Brooks A. CMV-specific CD8+ T-cell dynamics in the blood and the lung allograft reflect viral reactivation following lung transplantation Am. J. Transplant.6, 577–584 (2006).
  • Shlobin O, West E, Lechtzin N et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J. Immunol.176, 2625–2634 (2006).
  • Weinberg A, Hodges TN, Li S, Cai G, Zamora MR. Comparison of PCR, antigenemia assay and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J. Clin. Microbiol.38, 768–772 (2000).
  • Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK; American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant.9, 258–268 (2009).
  • Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am. Rev. Respir. Dis.150, 146–152 (1994).
  • Kelly JL, Albert RK, Wood DE, Raghu G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation59, 1144–1147 (1995).
  • Hertz MI, Jordan C, Savik SK et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J. Heart Lung Transplant.17, 913–920 (1998).
  • Zamora MR. Cytomegalovirus and lung transplantation. Am. J. Transplant.4, 1219–1226 (2004).
  • Humar A, Kumar D, Preiksaitis J et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am. J. Transplant.5, 1462–1468 (2005).
  • Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am. J. Transplant.8, 2111–2118 (2008).
  • Chmiel C, Speich R, Hofer M et al. Ganciclovir/valgnaciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin. Infect. Dis.46, 831–8390 (2008).
  • Valantine HA, Luikart H, Doyle R et al. Impact of cytomegalovirus hyoerimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation72, 1647–1652 (2001).
  • Zamora MR, Davis D, Leonard C; CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation80, 157–163 (2005).
  • Avery RK. Management of late, recurrent, and resistant cytomegalovirus in transplant recipients. Transplant Rev.21, 65–76 (2007).
  • Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J. Heart Lung Transplant.26, 41–47 (2007).
  • Neurohr C, Huppmann P, Leuchte P et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am. J. Transplant.5, 2982–2991 (2005).
  • Kumar D, Erdman D, Keshavjee S et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am. J. Transplant.5, 2031–2036 (2005).
  • Milstone AP, Brumble LM, Barnes J et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur. Respir. J.28, 131–137 (2006).
  • Hopkins P, McNeil K, Kermeen F et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am. J. Respir. Crit. Care Med.178, 876–881 (2008).
  • Shekar K, Hopkins PM, Kermeen FD, Dunning JJ, McNeil KD. Unexplained chronic anemia and leukopenia in lung transplant recipients secondary to parvovirus B19 infection. J. Heart Lung Transplant.27, 808–811 (2008).
  • Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transplant Int.20, 993–1015 (2007).
  • Iversen M, Burton CM, Vand S et al.Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J. Clin. Microbiol. Infect. Dis.26, 879–886 (2007).
  • Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J. Heart Lung Transplant.22, 258–266 (2003).
  • Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am. J. Respir. Crit. Care Med.173, 707–717 (2006).
  • Husain S, Paterson DL, Studer SM et al.Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation83, 1330–1336 (2007).
  • Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J. Clin. Microbiol.45, 1759–1765 (2007).
  • Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl. Infect. Dis.8, 213–218 (2006).
  • Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am. J. Transplant.6, 3008–3016 (2006).
  • Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis.39, 1563–1571 (2004).
  • Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect.53, 337–349 (2006).
  • Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347, 408–415 (2002).
  • Silveira FP, Kwak EJ, Paterson DL, Pilewski JM, McCurry KR, Husain S. Post-transplant colonization with non-aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J. Heart Lung Transplant.27, 850–855 (2008).
  • Chalermskulrat W, Sood N, Neuringer IP et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax61, 507–513 (2006).
  • Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am. J. Respir. Crit. Care Med.160, 1611–1616 (1999).
  • Chernenko SM, Humar A, Hutcheon M et al.Mycobacterium abscessus infections in lung transplant recipients: the international experience. J. Heart Lung Transplant.25(12), 1447–1455 (2006).
  • Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care7, 384–389 (2001).
  • Mason DP, Solovera-Rozas M, Feng J et al. Dialysis after lung transplantation: prevalence, risk factors and outcome. J. Heart Lung Transplant.26, 1155–1162 (2007).
  • Canales M, Youssef P, Spong R et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am. J. Transplant.6, 2157–2163 (2006).
  • Ishani A, Erturk S, Hertz MI et al. Predictors of renal function following lung or heart–lung transplantation. Kidney Int.61, 2228–2234 (2002).
  • Esposito C, De Mauri A, Vitulo P et al. Risk factors for chronic renal dysfunction in lung transplant recipients. Transplantation84, 1701–1703 (2007).
  • Stephany BR, Alao B, Budev M, Boumitri M, Poggio ED. Hyperlipidemia is associated with accelerated chronic kidney disease progression after lung transplantation. Am. J. Transplant.7, 2553–2560 (2007).
  • Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin. Transplant.22, 1–15 (2008).
  • Snell GI, Levvey BJ, Chin W et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J. Heart Lung Transplant.21, 540–546 (2002).
  • Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. Clin. Transplant.23(3), 351–360 (2009).
  • Groetzner J, Wittwer T, Kaczmarek I et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation81, 355–360 (2006).
  • Formica RN Jr, Lorber KM, Friedman AL et al. The evolving experience using everolimus in clinical transplantation. Transplant. Proc.36, 495S–499S (2004).
  • Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev. (Orlando)22, 125–130 (2008).
  • Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M. Patterns of pulmonary complications associated with sirolimus. Respiration73, 367–374 (2006).
  • Groetzner J, Kur F, Spelsberg F et al.; Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J. Heart Lung Transplant.23, 632–638 (2004).
  • Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J. Heart Lung Transplant.26, 557–564 (2007).
  • Tschopp O, Boehler A, Speich R et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am. J. Transplant.2, 167–172 (2002).
  • Stephenson A, Jamal S, Dowdell T et al. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest130, 539–544 (2006).
  • Grey AB, Ames RW, Matthews RD, Reid IR. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax48, 589–593 (1993).
  • Aris RM, Neuringer IP, Weiner MA et al. Severe osteoporosis before and after lung transplantation. Chest109, 1176–1183 (1996).
  • Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest117, 476–481 (2000).
  • Shane E, Papadopoulos A, Staron RB et al. Bone loss and fracture after lung transplantation. Transplantation68, 220–227 (1999).
  • Ferrari SL, Nicod LP, Hamacher J et al. Osteoporosis in patients undergoing lung transplantation. Eur. Respir. J.9, 2378–2382 (1996).
  • Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J. Clin. Endocrinol. Metab.90, 2456–2465 (2005).
  • Henderson K, Eisman J, Keogh A et al. Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J. Bone Miner. Res.16, 565–571 (2001).
  • Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J. Heart Lung Transplant.19, 736–743 (2000).
  • Aris RM, Lester GE, Renner JB et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation Am. J. Respir. Crit. Care Med.162, 941–946 (2000).
  • Cahill BC, O’Rourke MK, Parker S et al. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation72, 1251–1255 (2001).
  • Braith RW, Conner JA, Fulton MN et al. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J. Heart Lung Transplant.26, 132–137 (2007).
  • Legendre C, Marchetti P, Markell M et al. New-onset diabetes after transplantation: 2003 International consensus guidelines; proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation75, SS3–SS24 (2003).
  • Ollech JE, Kramer MR, Peled N et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. Eur. J. Cardiothorac. Surg.33, 844–848 (2008).
  • Hadjiliadis D, Madill J, Chaparro C et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin. Transplant.19, 773–778 (2005).
  • Pham PTT, Pham PCT, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Clin. Endocrinol. Metab.36, 873–890 (2007).
  • Celik S, Doesch A, Erbel C et al. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation86, 245–250 (2008).
  • Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation83, 1141–1150 (2007).
  • Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin. Nephrol.55, 39–44 (2001).
  • Kariyawasam HH, Gyi KM, Hodson ME, Cohen BJ. Anaemia in lung transplant patient caused by parvovirus B19. Thorax55, 619–620 (2000).
  • Hachem RR, Yusen RD, Chakinala MM, Aloush AA, Patterson GA, Trulock EP. Thrombotic microangiopathy after lung transplantation. Transplantation81, 57–63 (2006).
  • Mal H, Veyradier A, Brugière O et al. Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients. Transplantation81, 1628–1632 (2006).
  • Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl. Int.9, 68–75 (1996).
  • Davis RD Jr, Lau CL, Eubanks S et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J. Thorac. Cardiovasc. Surg.125, 533–542 (2003).
  • Maurer JR. The spectrum of colonic complications in a lung transplant population. Ann. Transplant.5, 54–57 (2000).
  • Reddy N, Wilcox CM. Diagnosis & management of cytomegalovirus infections in the GI tract. Expert Rev. Gastroenterol. Hepatol.1(2), 287–294 (2007).
  • Gilljam M, Chaparro C, Tullis E et al. GI complications after lung transplantation in patients with cystic fibrosis. Chest123, 37–41 (2003).
  • Dellon ES, Morgan DR, Mohanty SP, Davis K, Aris RM. High incidence of gastric bezoars in cystic fibrosis patients after lung transplantation. Transplantation81, 1141–1146 (2006).
  • Folch E, Shakoor H, Gomez J et al. Gastric bezoar after lung transplantation in non-cystic fibrosis patients and review of the literature. J. Heart Lung Transplant.26, 739–741 (2007).
  • Young LR, Hadjiliadis D, Davis RD et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest124, 1689–1693 (2003).
  • Hadjiliadis D, Davis RD, Steele MP et al. Gastroesophageal reflux disease in lung transplant recipients. Clin. Transplant.17, 363–368 (2003).
  • D’Ovidio F, Mura M, Tsang M et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J. Thorac. Cardiovasc. Surg.129, 1144–1152 (2005).
  • Ward C, Forrest IA, Brownlee IA et al. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. Thorax60, 872–874 (2005).
  • D’Ovidio F, Mura M, Ridsdale R et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am. J. Transplant.6, 1930–1938 (2006).
  • Stovold R, Forrest IA, Corris PA et al. Pepsin, a biomarker of aspiration in lung allografts: a putative association with rejection. Am. J. Respir. Crit. Care Med.175, 1298–1303 (2007).
  • Blondeau K, Mertens V, Vanaudenaerde BA et al. Gastro–oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur. Respir. J.31, 707–713 (2008).
  • Lord RV, Ho S, Coleman MJ et al. Cholecystectomy in cardiothoracic organ transplant recipients. Arch. Surg.133, 73–79 (1998).
  • Klima LD, Kowdley KV, Lewis SL et al. Successful lung transplantation in spite of cystic fibrosis-associated liver disease: a case series. J. Heart Lung Transplant.16, 934–938 (1997).
  • Meachery G, DeSoyza A, Nichoson A et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax63, 725–731 (2008).
  • Barshes NR, DiBardino DJ, McKenzie ED et al. Combined lung and liver transplantation: the United States experience. Transplantation80, 1161–1167 (2005).
  • Shitrit AB, Kramer MR, Bakal I, Morali G, Ben Ari Z, Shitrit D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann. Thorac. Surg.81, 1851–1852 (2006).
  • Sahi H, Zein NN, Mehta AC, Blazey HC, Meyer KH, Budev M. Outcomes after lung transplantation in patients with chronic hepatitis C virus infection. J. Heart Lung Transplant.26, 466–471 (2007).
  • Todd JL, Lakey J, Howell D, Reidy M, Zaas D. Portal hypertension and granulomatous liver disease in a lung transplant recipient due to disseminated atypical mycobacterial infection. Am. J. Transplant.7, 1300–1303 (2007).
  • Coley SC, Porter DA, Calamante F et al. Quantitative MR diffusion mapping and cyclosporine-induced neurotoxicity. Am. J. Neuroradiol.20, 1507–1510 (1999).
  • Sklar EM. Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? Am. J. Neuroradiol.27, 1602–1603 (2006).
  • Goldstein LS, Haug MT 3rd, Perl J 2nd et al. Central nervous system complications after lung transplantation. J. Heart Lung Transplant.17, 185–191 (1998).
  • Amital A, Shitrit D, Raviv Y et al. Development of malignancy following lung transplantation. Transplantation81, 547–551 (2006).
  • Yousem SA, Randhawa P, Locker J et al. Posttransplant lymphoproliferative disorders in heart–lung transplant recipients: primary presentation in the allograft. Hum. Pathol.20, 361–369 (1989).
  • Paranjothi S, Yusen RD, Kraus MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J. Heart Lung Transplant.20, 1054–1063 (2001).
  • Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epstein–Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation72, 1783–1786 (2001).
  • Ramalingam P, Rybicki L, Smith MD et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod. Pathol.15, 647–656 (2002).
  • Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest124, 1242–1249 (2003).
  • Gao SZ, Chaparro SV, Perlroth M et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J. Heart Lung Transplant.22, 505–514 (2003).
  • Montone KT, Litzky LA, Wurster A et al. Analysis of Epstein–Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery119, 544–551 (1996).
  • Aris RM, Maia DM, Neuringer IP et al. Post-transplantation lymphoproliferative disorder in the Epstein–Barr virus-naive lung transplant recipient. Am. J. Respir. Crit. Care Med.154, 1712–1717 (1996).
  • Wheless SA, Gulley ML, Raab-Traub N et al. Post-transplantation lymphoproliferative disease: Epstein–Barr virus DNA levels, HLA-A3, and survival. Am. J. Respir. Crit. Care Med.178, 1060–1065 (2008).
  • Oertel SH, Verschuuren E, Reinke P et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am. J. Transplant.5, 2901–2906 (2005).
  • Knoop C, Kentos A, Remmelink M et al. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin. Transplant.20, 179–187 (2006).
  • Veness MJ, Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer85, 1758–1764 (1999).
  • Minai OA, Shah S, Mazzone P et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J. Thorac. Oncol.12, 1404–1409 (2008).
  • Sathy SJ, Martinu T, Youens K et al. Symptomatic pulmonary allograft Kaposi’s sarcoma in two lung transplant recipients. Am. J. Transplant.8, 1951–1956 (2008).
  • Naderi AS, Farsian FN, Lee WM. Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis. Eur. J. Gastroenterol. Hepatol.20, 1115–1117 (2008).
  • Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am. J. Transplant.3, 619–625 (2003).
  • Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation87, 157–163 (2009).
  • Gross CR, Savik K, Bolman RM 3rd et al. Long-term health status and quality of life outcomes of lung transplant recipients. Chest108, 1587–1159 (1995).
  • Vermeulen KM, van der Bij W, Erasmus ME, Duiverman EJ, Koëter GH, TenVergert EM. Improved quality of life after lung transplantation in individuals with cystic fibrosis. Ped. Pulm.37, 419– 426 (2004).
  • Ramsey SD, Patrick DL, Lewis S, Albert RK, Raghu G. Improvement in quality of life after lung transplantation: a preliminary study. Washington University Medical Center Lung Transplant Study Group. J. Heart Lung Transplant.14, 870–877 (1995).
  • Myaskovsky L, Dew MA, McNulty ML et al. Trajectories of change in quality of life in 12-month survivors of lung or heart transplant. Am. J. Transplant.6, 1939–1947 (2006).
  • Sager JS, Kotloff RM, Ahya VN et al. Association of clinical risk factors with functional status following lung transplantation. Am. J. Transplant.6, 2191–2201 (2006).
  • Munro PE, Holland AE, Bailey M, Button BM, Snell GI. Pulmonary rehabilitation following lung transplantation. Transplant. Proc.41, 292–295 (2009).
  • Ericksson L. Heimburg, K, Mared L. Survival and functional status in patients 10 years after lung transplantation in Lund, Sweden. J. Heart Lung Transplant.26(Suppl. 1), S177 (2007).
  • Rutherford RM, Fisher AJ, Hilton C et al. Functional status and quality of life in patients surviving 10 years after lung transplantation. Am. J. Transplant.5, 1099–1104 (2005).
  • Gerbase MW, Soccal PM, Spiliopoulos A, Nicod LP, Rochat T. Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome. J. Heart Lung Transplant.27, 898–904 (2008).
  • Petrucci L, Ricotti S, Michelini I et al. Return to work after thoracic organ transplantation in a clinically-stable population. Eur. J. Heart Failure9, 1112–1119 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.